Current Report Filing (8-k)
September 20 2019 - 11:03AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
Current
Report Pursuant
to
Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported) September 13, 2019
PRESSURE
BIOSCIENCES, INC.
(Exact
Name of Registrant as Specified in its Charter)
MASSACHUSETTS
(State
or Other Jurisdiction of Incorporation)
001-38185
|
|
04-2652826
|
(Commission
File Number)
|
|
(IRS
Employer
Identification No.)
|
14
Norfolk Avenue, South Easton, MA
|
|
02375
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
(508)
230-1828
(Registrant’s
Telephone Number, Including Area Code)
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
None
|
|
N/A
|
|
N/A
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
Growth Company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers.
On
September 13, 2019, Mr. Daniel J. Shea accepted the position of Chief Financial Officer (“CFO”) of Pressure BioSciences,
Inc. (the “Company”).
Mr.
Shea, age 54, has over 30 years of experience in leading and advising financial organizations to the Company. Since January 2017,
he has operated Woodcliff Advisors LLC, a CPA advisory firm providing counsel to boards, CFOs and senior management. Through Woodcliff,
Mr. Shea personally filled CFO roles at public and private companies in the financial services and technology industries.
From 1998 to 2016, he was a Senior Vice President at Affiliated Managers Group, Inc., a publicly traded asset management holding
company with a long record of growth through acquisition. His core experience is in acquisitions, SEC reporting, internal
controls and the capital markets. Previously, he advised financial services firms at PricewaterhouseCoopers where his clients
included asset managers, banks, private equity firms, mutual funds and leasing companies. Mr. Shea is a certified public accountant
and earned his B.S. in Finance and Accounting from Boston College.
Family
Relationships
There
are no family relationships between Mr. Shea and any other executive officer or member of the board of directors of the Company.
Related
Party Transactions
There
are no related party transactions with regard to Mr. Shea reportable under Item 404(a) of Regulation S-K.
Material
Plans, Contracts, or Arrangements
In
connection with Mr. Shea’s appointment as the Company’s CFO, Mr. Shea will be paid a bi-weekly salary of $5,400.
Upon his appointment, Mr. Shea also received 52,550 non-qualified stock options and executed an Indemnification Agreement with
the Company.
Item 8.01 Other Events.
On
September 17, 2019, the Company issued a press release announcing the appointment of Mr. Shea.
A
copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Dated:
September 20, 2019
|
PRESSURE
BIOSCIENCES, INC.
|
|
|
|
By:
|
/s/
Richard T. Schumacher
|
|
|
Richard
T. Schumacher,
|
|
|
President
and Chief Executive Officer
|
Pressure Biosciences (CE) (USOTC:PBIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Pressure Biosciences (CE) (USOTC:PBIO)
Historical Stock Chart
From Sep 2023 to Sep 2024